Pharmacodynamic and Efficacy Studies of the Novel Proteasome Inhibitor NPI-0052 (marizomib) in a Human Plasmacytoma Xenograft Murine Model

Our previous study showed that the novel proteasome inhibitor NPI-0052 induces apoptosis in multiple myeloma (MM) cells resistant to conventional and bortezomib (Velcade™) therapies. In vivo studies using human MM-xenografts demonstrated that NPI-0052 is well tolerated, prolongs survival, and reduce...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Haematol
Asıl Yazarlar: Singh, Ajita V., Palladino, Michael A., Lloyd, G. Kenneth, Potts, Barbara, Chauhan, Dharminder, Anderson, Kenneth C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4427841/
https://ncbi.nlm.nih.gov/pubmed/20331453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08144.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller